Fight The Fakes’ member U.S. Pharmacopeia (USP) has recently published a suite of resources and tools to detect substandard and falsified COVID-19 treatments. The supply and demand imbalances caused by the COVID-19 pandemic has created a surge in substandard and falsified treatments and these resources aim to assist manufacturers, regulators, and quality control laboratories in helping to ensure quality COVID-19 treatments are being procured, produced, and distributed.

For their creation, USP collaborated with public health organizations, pharmacopeias, regulators, and manufacturers to help ensure quality and improve public trust. Among them, it is worth noting the ‘Responding to the surge of substandard and falsified health products triggered by the COVID-19 pandemic‘ white paper and the ‘USP Methods to Assist in Detecting Falsified Remdesivir‘, the first U.S. Food and Drug Administration approved treatment for hospitalized COVID-19 patients. 

Explore all USP’s resources here.